| Literature DB >> 30154386 |
Mabel Yin-Chun Yau1, Lu Xu2, Chien-Ling Huang3, Chi-Ming Wong4.
Abstract
Many mechanisms of obesity-induced cancers have been proposed. However, it remains unclear whether or not long non-coding RNAs (lncRNAs) play any role in obesity-induced cancers. In this article, we briefly discuss the generally accepted hypotheses explaining the mechanisms of obesity-induced cancers, summarize the latest evidence for the expression of a number of well-known cancer-associated lncRNAs in obese subjects, and propose the potential contribution of lncRNAs to obesity-induced cancers. We hope this review can serve as an inspiration to scientists to further explore the regulatory roles of lncRNAs in the development of obesity-induced cancers. Those findings will be fundamental in the development of effective therapeutics or interventions to combat this life-threatening adverse effect of obesity.Entities:
Keywords: ANRIL; H19; HOTAIR; cancer; lncRNA; obesity
Year: 2018 PMID: 30154386 PMCID: PMC6162378 DOI: 10.3390/ncrna4030019
Source DB: PubMed Journal: Noncoding RNA ISSN: 2311-553X
Summary of the recent findings on antisense non-coding RNA in the INK4 locus (ANRIL), H19, and HOX transcript antisense RNA (HOTAIR) in various human obesity-induced cancers.
| Type of Cancer |
|
|
|
|---|---|---|---|
| Endometrial cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Esophageal adenocarcinoma | Upregulated [ | Upregulated [ | Upregulated [ |
| Liver cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Pancreatic cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Colorectal cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Gallbladder cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Breast cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Ovarian cancer | Upregulated [ | Upregulated [ | Upregulated [ |
| Thyroid cancer | Upregulated [ | Downregulated [ | Upregulated [ |
Single-nucleotide polymorphisms (SNPs) in ANRIL locus associated with diabetes and cardiovascular diseases.
| SNP-ID | Related Diseases | Remarks | References |
|---|---|---|---|
| rs10757278 | Myocardial infarction | [ | |
| rs2891168 | Coronary artery disease | G-allele was associated with lower triglyceride level | [ |
| rs10811661 | Type 2 diabetes | [ | |
| rs10965215 and rs10738605 | Myocardial infarction | [ | |
| rs10757274 and rs1333042 | Coronary artery disease | [ | |
| rs10757278 | Major adverse cardio-vascular event (MACE) in patients starting on hemodialysis | [ | |
| rs564398 | Type 2 diabetes | Reduced β-cell proliferation | [ |
Figure 1The epigenetic state of imprinting control region on the Igf2-H19 locus determines the expression pattern. Regulation of maternal and paternal expression in the Igf2-H19 imprinted domain is controlled by genomic DNA methylation. The open boxes represent the genes Igf2 and H19, and the blue boxes represent the imprinting control region (ICR). The close lollipops represent methylated CpG islands. The yellow and red circles represent the CCCTC binding factor (CTCF) insulator protein and enhancer, respectively. The arrows from the boxes indicate expression of the genes. Igf2 and H19 genes are activated by the shared downstream enhancer, and their activations are dependent on the DNA methylation of the ICR. CCCTC binding factor (CTCF) is recruited to unmethylated ICR on the maternal allele that promotes the enhancer to activate the expression of H19 gene, but not of Igf2 gene. In contract, on paternal allele, ICR is hypermethylated that prevents the binding of CTCF to ICR. The overall outcomes are that the expression of H19 is repressed, but the expression of Igf2 is induced, from the paternal allele.
Targets of miR-675.
| Targeted mRNA | Targeted Region | Related Cancer or Diseases | References |
|---|---|---|---|
| FADD | 3′-UTR | Gastric cancer | [ |
| PTEN | 3′-UTR | Restenosis | [ |
| Vitamin D receptor | 3′-UTR | Colon cancer | [ |
| REPS2 | 3′-UTR | Esophageal squamous cell carcinoma | [ |
| RUNX1 | 3′-UTR | Gastric cancer | [ |
| TWIST1 | 3′-UTR | AFP-secreting hepatocellular carcinoma | [ |
| Retinoblastoma | 3′-UTR | AFP-secreting hepatocellular carcinoma, Colorectal cancer, glioma | [ |
| CALN1 | 3′-UTR | Gastric cancer | [ |
| c-Cbl | coding sequence | Breast cancer | [ |
| Cbl-b | coding sequence | Breast cancer | [ |
| TGFBI | 3′-UTR | Prostate cancer | [ |
| Cadherin 13 | 3′-UTR | Glioma development | [ |
Abbreviations: 3’UTR: 3’ untranslated region; AFP: α-fetoprotein.
Figure 2Proposed roles of long non-coding RNAs (lncRNAs) in obese-induced cancers. Many obese-related physiological changes such as nutrient availability, oxygen level, inflammatory cytokines, and metabolic hormones may affect the expression level (1) and post-transcriptional processing (2) of endogenous lncRNAs. Many lncRNAs can be transported to circulation and may serve as biomarkers or molecular diagnostic applications (3). Whether or not the exogenous lncRNAs contribute to the cancer progression is just emerging. In contrast, there is plentiful evidence showing that endogenous lncRNAs can regulate gene expression by diverse mechanisms. lncRNAs may act as scaffolds or molecular decoys, which directly interact with RNA binding proteins (RBPs; red circle) such as transcription factors and chromatin-modifying complexes to regulate the expression of proto-oncogenes and/or tumor suppressor genes (4). lncRNAs may act as endogenous sponges regulating gene expression via modulating microRNAs (miRNAs) availability (5 and 6).